Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Gains Speed In Race For NASH Therapies

Major Deals And Growing Pipeline

Executive Summary

NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.

You may also be interested in...



ADCs, Oncology Move To Fore In Korean Biopharma Alliances

Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends. 

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio

Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel